NIAID | Technology Transfer

Recovery of Recombinant Human Metapneumovirus (HPMV) From CDNA and Use of Recombinant HMPV in Immunogenic Compositions and As Vectors to Elicit Immune Responses Against HMPV and Other Human Pathogens

Read more about Recovery of Recombinant Human Metapneumovirus (HPMV) From CDNA and Use of Recombinant HMPV in Immunogenic Compositions and As Vectors to Elicit Immune Responses Against HMPV and Other Human Pathogens

US Application 60/451,119
Filed on 2003-02-28

Paramyxoviruses As Gene Transfer Vectors To Lung Cells

Read more about Paramyxoviruses As Gene Transfer Vectors To Lung Cells

US Application 60/326,535
Filed on 2001-09-28

P. Ariasi Polypeptides And P. Perniciosus Polypeptides Methods Of Use

Read more about P. Ariasi Polypeptides And P. Perniciosus Polypeptides Methods Of Use

US Application 60/425,852
Filed on 2002-11-12

Identification of Chimpanzee FAB Fragments by Repertoire Cloning and Production of a Full-Length Humanized IgG1 Antibody Highly Efficient Neutralization of Dengue Type 4 Virus

Read more about Identification of Chimpanzee FAB Fragments by Repertoire Cloning and Production of a Full-Length Humanized IgG1 Antibody Highly Efficient Neutralization of Dengue Type 4 Virus

US Application 60/528,161
Filed on 2003-12-08

Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in The 3'-UTR of Dengue Types 1,2,3, And 4

Read more about Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in The 3'-UTR of Dengue Types 1,2,3, And 4

US Application 60/436,500
Filed on 2002-12-23

Safer Attentuated Virus Vaccines with Missing or Diminished Latency of Infection

Read more about Safer Attentuated Virus Vaccines with Missing or Diminished Latency of Infection

US Application 60/423,603
Filed on 2002-11-05

HTLV-1-Cell Binding & Inhibition

Read more about HTLV-1-Cell Binding & Inhibition

US Application 60/422,803
Filed on 2002-10-30

Recovery of Recombinant Human Parainfluenza Virus Type 2 (HPIV2) From cDNA and Use of Recombinant HPIV2 in Immunogenic Compositions and as Vectors to Elicit Immune Responses Against PIV and Other Human Pathogens.

Read more about Recovery of Recombinant Human Parainfluenza Virus Type 2 (HPIV2) From cDNA and Use of Recombinant HPIV2 in Immunogenic Compositions and as Vectors to Elicit Immune Responses Against PIV and Other Human Pathogens.

US Application 60/412,053
Filed on 2002-09-18

Non-Viral Mammalian Expression Vector

Read more about Non-Viral Mammalian Expression Vector

US Application 60/413,117
Filed on 2002-09-24

Aerosolized Capreomycin for Inhibition of Pulmonary Tuberculosis

Read more about Aerosolized Capreomycin for Inhibition of Pulmonary Tuberculosis

US Application 60/410,601
Filed on 2002-09-12

Subscribe to NIAID